



## MINI ORAL SESSIONS SATURDAY, SEPTEMBER 24, 2016

### MINI01.01

#### Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3



Topic: Medical Oncology

**Alice T. Shaw,<sup>1</sup> David R. Spigel,<sup>2</sup> Daniel S.-W. Tan,<sup>3</sup> Dong-Wan Kim,<sup>4</sup> Ranee Mehra,<sup>5</sup> Sergey Orlov,<sup>6</sup> Keunchil Park,<sup>7</sup> Chong-Jen Yu,<sup>8</sup> Tony Mok,<sup>9</sup> Makoto Nishio,<sup>10</sup> Giorgio Scagliotti,<sup>11</sup> Santosh Sutradhar,<sup>12</sup> Dajana Cestic,<sup>12</sup> Enriqueta Felip<sup>13</sup>**  
<sup>1</sup>Massachusetts General Hospital, Boston/United States of America, <sup>2</sup>Sarah Cannon Research Institute, Nashville, TN/United States of America, <sup>3</sup>National Cancer Centre Singapore, Singapore/Singapore, <sup>4</sup>Seoul National University Hospital, Seoul/Korea, Republic of, <sup>5</sup>Fox Chase Cancer Center, Philadelphia, PA/United States of America, <sup>6</sup>St. Petersburg State Medical University, St. Petersburg/Russian Federation, <sup>7</sup>Innovative Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/Korea, Republic of, <sup>8</sup>National Taiwan University Hospital, Taipei City/Taiwan, <sup>9</sup>Chinese University of Hong Kong, Sha Tin/China, <sup>10</sup>Japanese Foundation for Cancer Research, Tokyo/Japan, <sup>11</sup>University of Torino, Torino/Italy, <sup>12</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ/United States of America, <sup>13</sup>Vall d'Hebron University, Barcelona/Spain

**Background:** Here we present efficacy outcomes in ALK-rearranged (ALK+) NSCLC patients with baseline (BL) brain metastases (BM) treated with the selective oral ALKi ceritinib in the ASCEND-1 (phase 1; NCT01283516) and ASCEND-3 (phase 2; NCT01685138) trials.

**Methods:** ALKi-naïve patients with ALK+ NSCLC and stable BL BM received ceritinib 750 mg/day. Efficacy analyses (by blinded independent review committee [BIRC]) assessed whole body responses for ASCEND-1 and -3 according to RECIST 1.0 and 1.1 criteria, respectively. Pooled intracranial responses were evaluated by BIRC (ASCEND-1, retrospectively; ASCEND-3, prospectively) in patients with measureable BL BM (RECIST 1.1).

**Results:** Of 26 and 50 ALKi-naïve patients with BL BM enrolled in ASCEND-1 and -3, respectively, 88.5% and

100% had prior chemotherapy and 57.7% and 54.0% had prior brain radiotherapy (RT); median times from prior RT to first ceritinib dose were 4.6 and 2.7 months. Ceritinib showed whole body and intracranial efficacy (Table). The most common AEs (ASCEND-1; ASCEND-3) were nausea (84.6%; 78.0%), diarrhea (92.3%; 76.0%) and vomiting (76.9%; 72.0%); 46 patients (ASCEND-1: 19; ASCEND-3: 27) had dose reductions and 4 patients (ASCEND-1: 3; ASCEND-3: 1) discontinued due to AEs.

	ASCEND-1	ASCEND-3	Pooled
Data cut-off	14 Apr 14	27 Jun 14	-
ALK-naïve patients with BL BM	26	50	-
Median duration of follow-up (range), months	12.3 (0.6-22.1)	7.5 (0.6-13.8)	-
<b>Whole body response (BIRC)</b>			
ORR [CI], %	65.4 [44.3, 82.8]	60.0 [45.2, 73.6]	-
Disease control rate [CI], %	76.9 [56.4, 91.0]	78.0 [64.0, 88.5]	-
Median DOR* [CI], months	NR [4.2, NR]	9.4 [5.6, NR]	-
Median PFS [CI], months	18.4 [4.6, NR]	11.0 [7.2, NR]	-
<b>Intracranial response (BIRC)</b>			
Patients with measurable BL BM	8	17	25
Intracranial ORR [CI], %	62.5 [24.5, 91.5]	58.8 [32.9, 81.6]	60.0 [38.7, 78.9]
Intracranial disease control rate [CI], %	62.5 [24.5, 91.5]	82.4 [56.6, 96.2]	76.0 [54.9, 90.6]
Median intracranial DOR* [CI], months	8.2 [5.6, NR]	NR [5.6, NR]	8.2 [5.6, NR]

\*Calculated for patients with confirmed CR or PR

CI, 95% confidence interval; NR, not reached

**Conclusion:** Clinically meaningful whole body and intracranial activity with an acceptable tolerability profile were observed in ALKi-naïve patients with ALK+ NSCLC and BL BM treated with ceritinib.

### MINI01.02

#### Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC



Topic: Medical Oncology

**Leora Horn,<sup>1</sup> Heather Wakelee,<sup>2</sup> Karen L. Reckamp,<sup>3</sup> George Blumenschein Jr.,<sup>4</sup> Jeffrey R. Infante,<sup>5</sup> Corey A. Carter,<sup>6</sup> Saiama N. Waqar,<sup>7</sup> Joel W. Neal,<sup>2</sup> Kimberly Harrow,<sup>8</sup> Jon P. Gockerman,<sup>9</sup> Gary Dukart,<sup>10</sup> Chris Liang,<sup>10</sup> James L. Gibbons,<sup>10</sup> Jennifer Hernandez,<sup>11</sup> Tera Newman-Eerkes,<sup>11</sup> Lee Lim,<sup>11</sup> Christine M. Lovly<sup>1</sup>**  
<sup>1</sup>Vanderbilt University Medical Center, Nashville, TN/United States of America, <sup>2</sup>Stanford Cancer Institute, Stanford, CA/United States of America, <sup>3</sup>City of Hope Comprehensive Cancer Center, Duarte/United States of America, <sup>4</sup>Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX/United States of America, <sup>5</sup>Sarah Cannon Research Institute, Nashville, TN/United States of America, <sup>6</sup>Walter Reed National Military Medical Center, Germantown, MD/